Antidote: new cancer detection test

Share this article:
Johnson & Johnson has received a lot of criticism lately because of the McNeil recalls of cold medicines, especially those for children. Factories must follow protocols which include sterility and proper oversights.  
At the same time, J&J is getting a badly needed pick-me-up from its Veridex division. They are bringing to market a new cancer detection test that was developed at Massachusetts General Hospital and is now being studied there and at three other major cancer centers around the country.                                                                                      
The test utilizes a microchip that resembles a lab slide. It is covered with 78,000 tiny prongs, coated with antibodies that bind to tumor cells. The chip is slid into the bloodstream where more than a billion normal cells bounce off it for every cancer cell that sticks. Then it's examined for its genetic make-up.
The amazing finding here is that cancer cells circulate in the blood even when the actual tumor is to be found in a discrete location such as the breast, colon, kidney or skin. The test has enormous potential for assessing and modifying cancer treatment, and has already been studied in this regard with trials appearing in major journals.                 
The potential of the test may even go beyond treatment and onto early detection, since we are making cancer cells long before a tumor actually develops.                                                         
It is part of the range and success of a large company like J&J that at the same time that it is receiving a repeated black eye for McNeil, and also receiving accolades for Veridex. If only the news media reported both these stories accurately and evenly.
Marc Siegel, MD, is an internist and professor of medicine at New York University and the author of False Alarm: The Truth About the Epidemic of Fear
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Headliner: Ipsen head leads continental charge

Headliner: Ipsen head leads continental charge

"When I look at the business, I actually see patients in my mind. I don't see numbers."

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets